Cardiovascular Disease, Statins, and HIV.
Human immunodeficiency virus (HIV)-infected patients are at an increased risk of serious, non-AIDS-defining comorbidities, even in the setting of viral suppression with combination antiretroviral therapy. This increased risk is due in part to immune dysfunction and heightened inflammation and immune activation associated with chronic HIV infection. Statins have wide-reaching immunomodulatory effects, and their use in the HIV-infected population may be of particular benefit. In this article, we review the pathogenesis of increased inflammation during HIV infection and how it contributes to the risk of cardiovascular disease among HIV-infected individuals. We then we review the immunomodulatory effects of statins and how they may attenuate the risk of cardiovascular disease and other comorbidities in this unique patient population.
Medical University of South Carolina, Charleston.
Allison Ross
AR
Eckard
Medical University of South Carolina, Charleston.
Eric G
EG
Meissner
Medical University of South Carolina, Charleston.
Inderjit
I
Singh
Case Western Reserve University, Cleveland, Ohio.
Grace A
GA
McComsey
D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D015897:Comorbidity; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007249:Inflammation / Q000150:complications; D012307:Risk Factors
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
HIV; cardiovascular disease; hydroxy-3-methylglutaryl coenzyme A reductase inhibitors; immune activation; inflammation; statins